Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Two new studies report GOT may improve health outcomes of stroke patients

Much of the devastation of stroke and head trauma is due to damage caused the overproduction of a substance in the brain called glutamate. Preventing this damage has been impossible, until now, as many drugs don't cross the so-called blood-brain barrier, and those that do often don't work as intended. But a method originally devised at the Weizmann Institute of Science may, in the future, offer a way to avert such glutamate-induced harm.

9 Feb 2011

Curaxis listed on Frankfurt Stock Exchange

Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp., today announced Curaxis' new listing on the Frankfurt Stock Exchange (FSE). Curaxis was at the FSE for its opening on February 8, 2011, and will trade under the symbol 8CX:GR.

9 Feb 2011

Specific gene variation linked to late-onset Alzheimer's

A new study from the Centre for Addiction and Mental Health (CAMH) has found evidence suggesting that a variation of a specific gene may play a role in late-onset Alzheimer's, the disease which accounts for over 90% of Alzheimer's cases. This innovative study has combined genetics and brain imaging to determine who may be at risk for developing late-onset Alzheimer's disease long before symptoms appear.

9 Feb 2011

Specific gene variation may play a role in late-onset Alzheimer's disease: New study

A new study from the Centre for Addiction and Mental Health has found evidence suggesting that a variation of a specific gene may play a role in late-onset Alzheimer's, the disease which accounts for over 90% of Alzheimer's cases. This innovative study has combined genetics and brain imaging to determine who may be at risk for developing late-onset Alzheimer's disease long before symptoms appear.

9 Feb 2011

Scientists develop novel technique to detect disordered protein folding

A team of scientists from The Scripps Research Institute and the University of California, San Diego have developed a novel technique to observe previously unknown details of how folded structures are formed from an intrinsically disordered protein.

9 Feb 2011

Positron anticipates expanded market opportunity for Attrius PET scanner

Positron Corporation a molecular imaging solutions company focused on nuclear cardiology, announced today that with the conditional U.S. Food and Drug Administration (FDA) approval of Eli Lilly's PET imaging agent Amyvid (florbetapir), it expects to see an expanded market opportunity for its Attrius® PET scanner.

8 Feb 2011

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

Metabolon, the leader in metabolomics, biomarker discovery and analysis, announced today the grant of US Patent No. 7,884,318 entitled "Systems, Methods, and Computer-Readable Medium for Determining Composition of Chemical Constituents in a Complex Mixture".

8 Feb 2011

Single molecule FRET techniques combined with wavelet transforms give new view of AMPA receptor

A digital signal processing technique long used by statisticians to analyze data is helping Houston scientists understand the roots of memory and learning, Alzheimer's and Parkinson's diseases and stroke.

8 Feb 2011

Elan 2010 total revenue increases 5% to $1,169.7 million

Elan Corporation, plc today reported its fourth quarter and full-year 2010 financial results and provided financial guidance for 2011.

8 Feb 2011

Higher vitamin D levels and sun exposure linked to lower risk of multiple sclerosis

People who spend more time in the sun and those with higher vitamin D levels may be less likely to develop multiple sclerosis (MS), according to a study published in the February 8, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology. MS is a chronic disease of the brain and spinal cord, usually with recurrent flare-ups of symptoms. It is often preceded by a first episode (or event) of similar symptoms lasting days to weeks.

8 Feb 2011

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2010.

8 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

Curaxis President comments on new Alzheimer's Association report

Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp., commented today on a new report by the Alzheimer's Association, titled "Generation Alzheimer's – the defining disease of the baby boomers", which demonstrates the devastating impact and size of Alzheimer's disease.

7 Feb 2011

AFA president issues statement acknowledging former President's contribution to Alzheimer's awareness

Eric J. Hall, president and CEO of the Alzheimer's Foundation of America, today noted the centennial birthday of President Ronald Reagan on February 6 by issuing a statement that acknowledged the former President's contribution to Alzheimer's awareness.

5 Feb 2011

U-M Medical School earns $368.7 million in NIH research funding during federal fiscal year 2010

University of Michigan Medical School physicians and scientists earned more than $368.7 million in National Institutes of Health research funding in federal fiscal year 2010, according to NIH data. In all, the School's faculty brought in $481.8 million in research funding from all sources in U-M fiscal year 2010.

5 Feb 2011

Stem cells delivered intranasally improve motor function in Parkinson's disease

Stem cells, delivered intranasally, were found to substantially improve motor function in Parkinson's disease in a study co-authored by William H. Frey II, Ph.D, Director of the Alzheimer's Research Center, part of HealthPartners Research Foundation. Frey collaborated with Lusine Danielyan, MD, of University Hospital of Tubingen in Germany.

4 Feb 2011

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.

3 Feb 2011

Merz introduces new educational website for patients with focal dystonias

In support of the focal dystonia community, Merz Pharmaceuticals today announced the launch of a new educational website, FocalDystoniaExchange.com, where people affected by certain focal dystonias, as well as caregivers, family and friends, can learn more about the conditions and access helpful resources. For people who suffer from focal dystonias, completing simple, everyday tasks can be a difficult and challenging process.

3 Feb 2011

Older people with metabolic syndrome may face high risk of developing memory loss

Older people with larger waistlines, high blood pressure and other risk factors that make up metabolic syndrome may be at a higher risk for memory loss, according to a study published in the February 2, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

3 Feb 2011

Study identifies effects of multiple previous concussions on high school students

A previous study of ex-NFL players showed that the damage caused by concussions occurs in the same region of the brain as damage caused by Alzheimer's disease, resulting in increased concern over post-concussion related injuries and trauma of athletes. Philip Schatz Ph.D., professor of psychology, and his associates recently published a study in Neurosurgery that identifies potentially enduring effects of multiple previous concussions on high school students.

2 Feb 2011

Alzheimer's Disease News and Research

Further Reading

Two new studies report GOT may improve health outcomes of stroke patients

Curaxis listed on Frankfurt Stock Exchange

Specific gene variation linked to late-onset Alzheimer's

Specific gene variation may play a role in late-onset Alzheimer's disease: New study

Scientists develop novel technique to detect disordered protein folding

Positron anticipates expanded market opportunity for Attrius PET scanner

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

Single molecule FRET techniques combined with wavelet transforms give new view of AMPA receptor

Elan 2010 total revenue increases 5% to $1,169.7 million

Higher vitamin D levels and sun exposure linked to lower risk of multiple sclerosis

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

Curaxis President comments on new Alzheimer's Association report

AFA president issues statement acknowledging former President's contribution to Alzheimer's awareness

U-M Medical School earns $368.7 million in NIH research funding during federal fiscal year 2010

Stem cells delivered intranasally improve motor function in Parkinson's disease

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Merz introduces new educational website for patients with focal dystonias

Older people with metabolic syndrome may face high risk of developing memory loss

Study identifies effects of multiple previous concussions on high school students

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News